

Influenza A Appears Resistant to Oseltamivir

BY SHERRY BOSCHERT

The dominant strain of influenza A during the current flu season is nearly completely resistant to oseltamivir because of a mutation that leaves its virulence intact, according to two studies that upset long-held ideas about oseltamivir-resistant influenza A (H1N1) viruses.

Findings from a third study bolster the rationale for widespread vaccination.

Taken together, the findings from these three studies should motivate more people to get annual influenza vaccinations, especially health care workers, since treatment options are now more limited, said Dr. Gregory A. Poland, who was not a participant in the studies. He is the American College of Physicians liaison to the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP).

In the first study, Dr. Nila J. Dharan of the CDC's influenza division in Atlanta, and associates, tested 268 influenza A (H1N1) isolates from the 2008-2009 season and found that 99% were oseltamivir (Tamiflu) resistant (JAMA 2009 [doi:10.1001/jama.2009.294]).

Such findings shore up concerns raised by a December 2008 CDC health advisory that reported resistance to oseltamivir in 98% of 50 influenza A (H1N1) viruses from 12 states in the early part of the 2008-2009 influenza season. As recently as the 2006-2007 influenza season, oseltamivir-resistant influenza was very uncommon. In the 2007-2008 season, however, influenza A (H1N1) comprised 19% of circulating influenza viruses, and 12% of 1,155 H1N1 viruses tested from 45 states showed oseltamivir resistance, according to Dr. Dharan and associates. About 55% of influenza types isolated so far by the CDC in the 2008-2009 season are oseltamivir-resistant H1N1.

Previously it was thought the mutation conferring oseltamivir resistance weakens the virus' ability to be transmitted from person to person and to sicken or kill, but Dr. Dharan's study and another by Dr. Jairo Gooskens dispel those notions. In Dr. Dharan's study, 3% of 142 patients whose resistant viruses were tested by the CDC died of influenza.

Dr. Gooskens of Leiden (the Netherlands) University, and associates performed gene sequencing analysis on viruses from four patients in a nosocomial outbreak of oseltamivir-resistant influenza A (H1N1) at one hospital. The virus spread from the index patient to three others, two of whom died, and possibly to five health care workers (JAMA 2009 [doi:10.1001/jama.2009.297]).

In neither study did use or overuse of oseltamivir appear to contribute to viral resistance, a fact that "frankly, has caught us with our intellectual pants down. That really did surprise us," said Dr. William Schaffner, chair of preventive medicine at Vanderbilt University, Nashville, Tenn., and the Infectious Diseases Society of America liaison to the ACIP. He did not participate in the studies.

At an ACIP meeting held in late February, committee members "acknowledged that we are still a little flummoxed about how it is that these viruses could have spread not only within the United States but globally so rapidly," he said.

The third study analyzed more than a million active-duty members of the U.S. military during three influenza seasons. The trivalent inactivated vaccine (TIV) was more effective than was the live at-

tenuated influenza vaccine (LAIV) or no vaccine in protecting this annually immunized cohort, reported Zhong Wang, Ph.D., of the Armed Forces Health Surveillance Center, Silver Spring, Md., and associates (JAMA 2009;301:945-53).

The study investigators all reported having no conflicts of interest related to the studies. Dr. Schaffner has been a consultant for, or received funding from, GlaxoSmithKline, Novartis, Sanofi Pas-

teur, and MedImmune, which make influenza vaccines or treatments. Dr. Poland has been a consultant for, or received funding from, Dynavax, Novavax, Merck & Co., GlaxoSmithKline, Novartis Vaccines, CSL Biotherapies, PowerderMed, Avianax, and Protein Sciences. ■

Updates on CDC influenza antiviral recommendations can be monitored at www.cdc.gov/flu/professionals/antivirals.

Indications and usage

Levemir® is indicated for once- or twice-daily subcutaneous administration for the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia.

Important safety information

Levemir® is contraindicated in patients hypersensitive to insulin detemir or one of its excipients.

Hypoglycemia is the most common adverse effect of all insulin therapies, including Levemir®. As with other insulins, the timing of hypoglycemic events may differ among various insulin preparations. Glucose monitoring is recommended for all patients with diabetes. Levemir® is not to be used in insulin infusion pumps. Any change of insulin dose should be made cautiously and only under medical supervision. Concomitant oral antidiabetes treatment may require adjustment.

Inadequate dosing or discontinuation of treatment may lead to hyperglycemia and, in patients with type 1 diabetes, diabetic ketoacidosis. Levemir® should not be diluted or mixed with any

other insulin preparations. Insulin may cause sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy. Dose and timing of administration may need to be adjusted to reduce the risk of hypoglycemia in patients being switched to Levemir® from other intermediate or long-acting insulin preparations. The dose of Levemir® may need to be adjusted in patients with renal or hepatic impairment.

Other adverse events commonly associated with insulin therapy may include injection site reactions (on average, 3% to 4% of patients in clinical trials) such as lipodystrophy, redness, pain, itching, hives, swelling, and inflammation.

*Whether these observed differences represent true differences in the effects of Levemir®, NPH insulin, and insulin glargine is not known, since these trials were not blinded and the protocols (eg, diet and exercise instructions and monitoring) were not specifically directed at exploring hypotheses related to weight effects of the treatments compared. The clinical significance of the observed differences in weight has not been established.

For your patients with type 2 diabetes, start once-daily Levemir®

Levemir® helps patients with diabetes achieve their A1C goal.^{2,3}

- 24-hour action at a once-daily dose^{4,5}
- Provides consistent insulin absorption and action, day after day^{4,6,7}
- Less weight gain^{8*}

To access complimentary e-learning programs, visit novomedlink.com/Levemir

References: 1. Data on file. Novo Nordisk Inc, Princeton, NJ. 2. Meneghini LF, Rosenberg KH, Koenen C, Meriläinen MJ, Lüddecke H-J. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. *Diabetes Obes Metab*. 2007;9(3):418-427. 3. Hermansen K, Davies M, Derzinski T, Ravn GM, Clauson P, Home P, for the Levemir Treat-to-Target Study Group. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes. *Diabetes Care*. 2006;29(6):1269-1274. 4. Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. *Diabetes Obes Metab*. 2007;9(3):290-299. 5. Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. *Clin Ther*. 2006;28(10):1569-1581. 6. Danne T, Endahl L, Haahr H, et al. Lower within-subject variability in pharmacokinetic profiles of insulin detemir in comparison to insulin glargine in children and adolescents with type 1 diabetes. Presented at: 43rd Annual Meeting of the European Association for the Study of Diabetes; September 17-21, 2007; Amsterdam, Netherlands. Abstract 0189. 7. Heise T, Nosek L, Rønn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. *Diabetes*. 2004;53(6):1614-1620. 8. Data on file. NDA21-536. Novo Nordisk Inc, Princeton, NJ.



Please see brief summary of Prescribing Information on adjacent page.

FlexPen® and Levemir® are registered trademarks of Novo Nordisk A/S.
© 2008 Novo Nordisk Inc. 133236-R2 November 2008

